Good summary LO. I'd be happy with 2 of those 3 scenarios.
Like you said, 20mil does sound like much but when added to current cash, that would give the company a cash backing of more than 10c per share plus a quick pathway forward to commerciaise BIT225. Those two things alone would increase the value of the stock dramatically. Moving on to progress other drugs candidates would be a massive bonus as it would create a bigger pipline and more opportunities for further deals. All three would derisk the stock.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $5.075K | 2.537M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 31028047 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 15909523 | 21 |
View Market Depth
| Last trade - 11.26am 21/07/2025 (20 minute delay) ? |
| BIT (ASX) Chart |